Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Myrbetriq is a prescription beta-3 adrenergic receptor agonist containing mirabegron. Its extended-release tablets treat overactive bladder in adults and neurogenic detrusor overactivity in children age 3 and older weighing at least 35 kg. Myrbetriq Granules are a separate extended-release oral suspension formulation used for pediatric neurogenic detrusor overactivity from age 3.
read more about myrbetriq ...Mirabegron activates beta-3 adrenergic receptors in the bladder's detrusor muscle, causing relaxation during the urine storage phase. This increases bladder storage capacity and helps reduce urinary urgency, urinary frequency, and urge urinary incontinence. Its activity differs from antimuscarinic bladder medicines.
Myrbetriq tablets are used in adults with overactive bladder symptoms and eligible pediatric patients with neurogenic detrusor overactivity. Children weighing less than 35 kg use Myrbetriq Granules rather than the tablets. Adult overactive bladder treatment can be given alone or with solifenacin. Patients with severe uncontrolled hypertension are not recommended to receive mirabegron.
Adults with overactive bladder start at 25 mg extended-release tablets once daily, increasing to 50 mg after four to eight weeks when needed. Pediatric patients age 3 and older weighing at least 35 kg follow the same tablet regimen for neurogenic detrusor overactivity. Children weighing 11 kg to less than 22 kg start Myrbetriq Granules at 3 mL daily, while those weighing 22 kg to less than 35 kg start at 4 mL daily. Granule dose increases are weight-based. Tablets and granules are not interchangeable milligram for milligram.
Myrbetriq can increase blood pressure and cause urinary retention, particularly in patients with bladder outlet obstruction or those taking antimuscarinic medicines. Serious angioedema involving the face, tongue, or throat has also been reported. Mirabegron inhibits CYP2D6, increasing exposure to certain medicines metabolized by that enzyme. Blood pressure, urination, and potential drug interactions are assessed during treatment.
Myrbetriq treats overactive bladder in adults and neurogenic detrusor overactivity in eligible children.
The recommended starting dose is 25 mg once daily, with an increase to 50 mg after four to eight weeks when needed.
Yes. Children age 3 and older with neurogenic detrusor overactivity can receive age- and weight-appropriate tablets or granules.
Yes. Myrbetriq can raise blood pressure and is not recommended for patients with severe uncontrolled hypertension.
DailyMed - MYRBETRIQ (mirabegron) extended-release tablets and granules. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d. Date Accessed October 16, 2026.
Mirabegron. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547887/. Date Accessed October 16, 2026.
Mirabegron. MedlinePlus. https://medlineplus.gov/druginfo/meds/a612038.html. Date Accessed October 16, 2026.
Mirabegron. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Mirabegron. Date Accessed October 16, 2026.
Mirabegron. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK538513/. Date Accessed October 16, 2026.